 HALIFAX, Nova Scotia--BUSINESS WIRE--Appili Therapeutics Inc. TSX: APLI; OTCQX: APLIF the Company or Appili, a biopharmaceutical company focused on anti-infective drug development, today announced that it has signed a collaboration, development and supply agreement with Dr. Reddys Laboratories Ltd. BSE:500124, NSE:DRREDDY, NYSE:RDY, Dr. Reddys and Global Response Aid GRA. This agreement follows on and is harmonized with the previously announced global licensing transaction 